

**Approximate study time:** 1.5 hours**Level:** Introductory/Intermediate**Audience:** Research, Regulatory, Manager, Other**Category:** Nonclinical, Clinical, Regulatory Submissions**Region:** Europe, USA, Other**CPD Points:** 1.5**Module outline**

- Module overview
- Study design
- Sampling practice and outcomes
- Data analysis
- Special populations
- Generics and bioequivalence
- Assessment

zenosis Conducting Pharmacokinetic and Pharmacodynamic Studies
Special populations

Case study impaired elimination

A PK study in an organ dysfunction may have significance for registration of the drug that is out of proportion to the medical relevance of the dysfunction. Click on the link to explore the case of a small, water-soluble molecule which is metabolized only very slowly.

Impaired elimination

Lower dysfunction
A separate clinical study on the impact of liver damage on the PK of the drug may not be required in a nonclinical (Effect of liver damage may be studied in Phase II). However, the effect of structural liver damage, changes in the enzymatic capacity of the remaining hepatic cells, and hence on drug action, is difficult to predict. Even if metabolism is only a minor route of elimination, there may be great reserves when a PK study in hepatic impairment might be of high medical relevance, e.g. accumulation of toxic metabolites. Thus a separate clinical study in liver damage may be thought necessary, even if it is not mandatory for drug registration.

Screen 611

zenosis Conducting Pharmacokinetic and Pharmacodynamic Studies
Generics and bioequivalence

What is bioequivalence testing?

Interchangeability in USA
USF regulations are concerned with the full interchangeability of a generic with its reference product. To be approved the manufacturer of the generic must be shown to be therapeutically equivalent. FDA allows two products to be therapeutically equivalent if they are:

- pharmacologically equivalent – i.e. they have the same active ingredient, dosage form, strength, and route of administration – and
- bioequivalent – i.e. they have sufficiently similar bioavailability.

Screen 612

This module extends the learner's understanding of pharmacokinetic and pharmacodynamic studies from the basics described in our companion module PKPD01, An Introduction to Pharmacokinetics and Pharmacodynamics in Drug Development and Registration. It provides detail on a variety of aspects of such studies: design, sampling, data analysis, research in special populations, and bioequivalence testing.

**Who will benefit from this module?**

Pharmacologists, nonclinical researchers, clinical researchers, regulatory affairs staff, and others who contribute to drug development and registration will benefit from this module.

**Learning objectives**

- Summarise the advantages, and how to counteract the main weakness, of the core design of choice for many pharmacokinetic and pharmacodynamic studies
- Adopt good sampling practice
- Discuss non-compartmental and compartmental data analysis
- Describe the responsibilities of a clinical investigator.
- Describe the rationale and characteristics of studies in special populations
- Describe how to carry out bioequivalence testing

**Module outline****Module overview**

An outline of the module's scope and objectives, and notes on terminology.

Study design

In this session we discuss the core design of choice for many PK and PD studies: crossover. We outline its advantages and how to counteract an important weakness, which is the carry-over effect.

Sampling practice and outcomes

Arguably the most important aspect of the design of a PK or PD study is the sampling schedule. How many samples should be taken per subject and at which time points after dosing? Choice of these factors is crucial in minimising bias and maximising the precision of results. In this session we explain principles of good practice in sampling.

Data analysis

In this session, after introducing the principal pharmacokinetic parameters, we describe the PK and PK/PD characteristics of each drug administration route. We discuss the different medical-scientific questions to be addressed by PK/PD research for the different routes.

Special populations

Drug development entails research not only into the target population as a whole but into sub-populations with a common demographic or health characteristic that may produce treatment outcomes that differ significantly from the average. In this session we discuss such special populations and how they are studied.

Generics and bioequivalence

Licensing of generic drugs is an area in which pharmacokinetic studies constitute the prime determining factor. In the great majority of cases the test that determines the licensing of a generic drug is a comparison of its plasma concentration–time course with that of the product it copies – a bioequivalence test – to assess whether they are sufficiently similar. In this session we describe how to carry out bioequivalence testing.

Assessment

Multiple-choice mastery assessment.